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Table. 1-year outcomes according to bifurcation treatment
Bifurcation
(n=1,317)
No bifurcation
(n=7,266) p value
MACE (Cardiac death, MI or TLR) 8.79% 6.48% 0.002
Cardiac death 0.79% 1.10% 0.31
MI (any) 4.02% 3.05% 0.067
Peri-procedural MI 2.28% 1.27% 0.004
TVR (any) 8.58% 6.41% 0.004
Deﬁnite/probable ST 0.70% 0.86% 0.56
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Background: ADAPT-DES was a prospective, multicenter, real-world registry of
8,583 consecutive pts at 11 international centers undergoing percutaneous coronary
intervention (PCI) with DES designed to determine the frequency, timing, and
correlates of early and late stent thrombosis (ST). Treatment of bifurcation lesions has
been shown to be associated with an increased risk of ST and worse clinical outcome.
We therefore analyzed the impact of bifurcation PCI on outcomes at 1 year.
Methods: Univariable and a fully adjusted multivariable analysis including propensity
score stratiﬁcation were performed to determine the relationship between bifurcation
PCI and subsequent events.
Results: During the index procedure, bifurcation lesions were treated in 1,317
(15.7%) of 8,583 pts. Pts in the bifurcation group were less likely to be female (22.2%
vs. 26.6%, p<0.001), diabetic (28.2% vs. 33.2%, p<0.001), or have ACS (47.2% vs.
52.5%, p<0.001). Post-procedure platelet reactivity was lower among patients
undergoing bifurcation PCI (mean P2Y12 PRU 183 vs. 189, p¼0.017). Pts with
bifurcation PCI had more total stents (2.10 vs. 1.65, p<0.0001) resulting in longer
total stent length (39.2 vs. 31.2 mm, p<0.0001). Bifurcation lesions were more often
in LAD territory (48.9% vs. 37.0%, p<0.0001). Both branches were stented in 19.1%
of all bifurcation lesions, and ﬁnal kissing was done in 46.1%. The 1 year unadjusted
rates of adverse outcomes are shown in the Table. In propensity adjusted models,
bifurcation treatment was not independently associated with 1-year MACE (HR [95%
CI] ¼ 1.13 [0.89, 1.42, p¼0.32), cardiac death (0.75 [0.31, 1.54], p¼0.43), ST (0.64
[0.30, 1.36], p¼0.24), or TVR (1.13 [0.89, 1.43], p¼0.31).
Conclusions: These data, drawn from a large prospective registry of contemporary
DES use, show that bifurcation lesion treatment is frequent, and is not necessarily
associated with a worse prognosis at 1 year.B126 JACC Vol 62/18/Suppl B j October 27–November 1, 2TCT-404
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Background: POLBOS is the randomized, prospective, multicentre study planned to
compare two intervention strategies for bifurcation treatment: provisional T-stenting
(PTS) with any regular drug-eluting stent (DES) and dedicated bifurcation paclitaxel-
eluting stent BiOSS Expert (Balton, Poland).
Methods: Between September 2010 and December 2012 in four centers in Poland
patients with stable CAD or NSTE-ACS were randomized to the group where BiOSS
Expert was implanted or to the group where regular DES was used. An angiographic
control was planned at 12 months in all patients. The primary end-point of the study is
the rate of death, MI, ST and TLR after 12 months. At the time of TCT 2013 complete
clinical 9-month follow-up will be available as well as 90% of angiographic controls
after 12 months.
Results: BiOSS Expert was implanted in 119 patients (49.4%) and regular DES was
implanted in 122 patients (50.6%). The average age of patients did not differ signif-
icantly between groups (BiOSS vs DES: 66.5 vs 66.8 yrs). In BiOSS group there were
signiﬁcantly more patients with NSTE-ACS (9.6% vs 3.5%), diabetes (32.2% vs
16.8%), prior MI and prior CABG. In DES group there were more patients addicted to
smoking (13% vs 22.1%). The dominant vessel was LAD (BiOSS vs DES: 52.1% vs
70.5%) followed by LMS (22.7% vs 13.9%, respectively). In DES group 35.4% of
stents eluted paclitaxel (PES). There were following nominal stent parameters in
BiOSS group: 3.690.36mm x 2.990.36mm x 16.961.44mm and in DES group:
3.270.49mm x 20.66.96 mm. Except for 2 (1.64%) cases in DES group and 1
(0.84%) in BiOSS group all stents were implanted successfully. There were 16%
(BiOSS) and 11.2% (DES) cases with second stent implanted within the side branch.
At six months all patients were uneventful. Up to now control angiography was
performed in 76% of patients in BiOSS group and in 74% in DES group. TLR was,
respectively, 10.99% vs 8.9% (p ¼ 0.5). Nevertheless, within DES group TLR in PES
subgroup was 12.8% and in –olimus subgroup – 5.7%
Conclusions: 9-month follow-up showed that BiOSS Expert provides satisfactory
results which seem to be inferior to those obtained by means of –limus eluting stents,
but comparable with those of PES.
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Background: The provisional T-stenting (PTS) is the recommended strategy for the
coronary bifurcation treatment. However, results obtained with use of regular drug
eluting stents (DES) are not optimal and relatively often associated with a side branch
compromise and restenosis. Dedicated bifurcation stents are claimed to be a solution
for these complications. POLBOS II study is the continuation of POLBOS study,
which paclitaxel-eluting stent BiOSS Expert was assessed in.
Methods: It is a randomized multicenter study planned to compare two strategies for
the bifurcation treatment – PTS with any regular DES or with a dedicated bifurcation
sirolimus-eluting stent BiOSS LIM (Balton, Poland) in patients with CAD or NSTE-
ACS. An angiographic control was planned at 12 months in all patients. The primary
end-point of the study is the rate of death, MI, ST and TLR after 12 months. The aim
is to enroll 120 patients (60 in each group).
Results: The enrollment started in November 2012. To date, 75 patients (64% males)
were randomized (40 inBiOSS group, 35 inDES group). The average agewas 649 yrs.
The dominant vessel was LAD (50%) followed by LMS (33%). 72% of cases were true
bifurcations. All stents were implanted successfully. There were 12.5 and 14.3% of013 j TCT Abstracts/POSTER/Bifurcation and Left Main Interventions
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Scases, respectively in a DES group and BiOSS group, with a stent implanted in SB.
Nominal stent parameterswere as followed: inBiOSS group: 3.790.34x16.21.42mm
vs 3.570.28x18.564.44mm). Up to now there was noMACE.At the time of TCTwe
are to ﬁnish the enrollment and present initial 3-month clinical follow-up.
Conclusions: Collected data demonstrate comparable immediate clinical results for
both studied group. Full data enable to answer the question if BiOSS LIM
comparable to regular DES and if it is superior to BiOSS Expert stent assessed in
POLBOS study.
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Background: Coronary artery disease of left main stem (LMS) is a particular form of
atherosclerosis, and the most optimal treatment is still debated. The aim of this study
was to assess the effectiveness and safety proﬁle of the distal LMS stenosis treatment
with the dedicated bifurcation stent BiOSS: in subgroup I paclitaxel-eluting BiOSS
Expert (Balton, Poland) and in subgroup II sirolimus-eluting BiOSS LIM.
Methods: The enrollment of patients with CAD and NSTE-ACS started in January
2010 in two centers in Poland and Bulgaria. Decision for LMS stenting was based on the
Heart Team consensus. We are to gather the group of 100 patients equally distributed.
Control angiography is planned at 12 month is all patients. The primary end point is the
rate of death, myocardial infarction, in-stent thrombosis or target lesion revasculari-
zation (TLR) at 12 month after PCI. Here, we present 6-month clinical data.
Results: So far we have enrolled 86 patients (56 in BiOSS Expert group, 30 in BiOSS
LIM group). The average age was 62.8  10.1 yrs and 20% were female. PCI was
performed in NSTE-ACS in 16% of patients. Moreover, 78% were with hypertension,
60%with dyslipidemia, 24%with diabetes, 37%with prior MI, 45%with prior PCI and
11% with prior CABG. The mean SYNTAX score was 22.97  6.4 and logistic
EuroScore – 4.1% 2.8% (NS differences between subgroups). All BiOSS stents were
implanted successfully. The nominal stent parameters were as followed: subgroup
I - 4.01 0.26 mm x 3.37 0.37 mm x 17.67 1.27 mm and subgroup II - 3.98 0.23
mm x 3.23  0.17 mm x 16.87  2.27 mm. Side branch stent was implanted,
respectively, in 26% and 23% of patients. 71% of procedures were performed from
radial access, whereas 29% from femoral access. In 20% of cases 7F catheter was
applied, and in 80% - 6F. At 6 months there were no death or MI. Target lesion
revascularization was performed in 4 patients (4.6%) only in BiOSS Expert subgroup.
Conclusions: Dedicated bifurcation BiOSS stents seems feasible devices with
promising effectiveness and safety proﬁle in distal LMS bifurcation stenosis. Full
angiographic data will answer the question if the used drug is more important or
maybe the stent design is crucial.
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Background: There is uncertainty about inﬂuence of periprocedural ischemia and
myonecrosis on long-term results of coronary artery bifurcation stenting (PCI).
Restenosis remains an unresolved issue, and identiﬁcation of its predictive factors
may allow further insight into the underlying process. The aim of the study is
to explore the inﬂuence of end-procedural ischemia (detected with intracoronary
electrocardiography (icECG) and post-procedural myonecrosis (troponin and creatine-
phosphokinase – MB (CK-MB) elevation) on revascularization rates (TLR) at 12
months after PCI.
Methods: After placement of intracoronary guidewires in main branch (MB) and side
branch (SB) an uninsulated proximal ends of wires were connected to unipolar V
leads. Intracoronary unipolar ECGs (icECG) were recorded before, during and after
stent placement and at the end of procedure. The maximal ST-segment elevation
during intervention and 5 min after the procedure was recorded in SB and MB.
Results: We studied 142 patients with different types of bifurcation lesions with
stable/unstable angina: 69% were males, mean age 699, diabetics 33.6%. The main
treated vessel was LAD (77%). True bifurcation lesions (Medina xx1) were 53%. 131
(92%) patients were followed for more than 12 months. The TLR at 12 months of
follow-up was 7.6% (10/131). There was a signiﬁcant difference in the TLR rate
among patients with ﬁnal ST elevation in the MB territory – MB STE (-): 3.7% (3/82)
vs.14.3% (7/49) MB STE (+), p¼.032. On the other hand we found no signiﬁcant
difference in TLR among patients with ﬁnal SB ST elevation – SB STE (+) 8.9%JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr(4/41) vs. 7.0% (6/86) SB STE (-) p¼.469. The ﬁnal ST elevation in the main branch
at the end of bifurcation PCI was the only independent predictor for TLR at 12 months
on multivariate regression analysis (OR¼5.3.19, CI 1.197 – 23.809, p¼.028; model
including renal failure, CKMB preinterventional, SB ﬁnal %DS, MB ﬁnal STE, MB
postdilatation, occlusion of secondary branch).
Conclusions: The end-procedural ischemia detected by intracoronary ECG in the
main branch territory is a sensitive newly discovered factor for prediction of in-stent
restenosis after coronary bifurcation stenting.
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Background: Application of drug-coated balloons (DCB) for the treatment of in-stent
restenosis has been proven to show clinical beneﬁts in several randomized trials.
While the superiority of DCBs compared to DES in de novo lesions is still contro-
versial, there have been promising results when used in small coronary vessels and
bifurcation lesions. While so far most bifurcation studies investigated the outcome
after sequential application of DCBs to the main (MB) and side branch (SB) with
provisional T-stenting of the MB with a BMS, we report ﬁrst results after DCB only
intervention without additional stenting of the MB or SB.
Methods: Between January and July 2011 we performed 47 DCB interventions
in bifurcation lesions with SB  2 mm. Bifurcations were treated with a DCB
if they showed an acceptable angiographic result after careful preparation as
recommended by the German Consensus Group. All patients were scheduled for
follow-up angiography 4 months after index procedure. Patients who did not
attend to the follow-up were interviewed for MACE within 4 months after
index procedure.
Results: Most interventions could be performed according to the planned DCB
only strategy without additional stenting (n¼42). Follow-up angiograms were
obtained in 32 DCB only interventions. Most lesions were de novo lesions (n¼30)
with 40.6% located in the bifurcation distal left main coronary artery (LM)/left
anterior descending artery (LAD)/left circumﬂex artery (LCX). Others were found
in LAD/diagonal branch (21.9%), LCX/obtuse marginal branch (18.7%) or right
coronary artery/right posteriolateral artery/right posterior descending artery
(18.7%). 4 months after index procedure no patient had experienced any MACE.
Follow-up angiograms showed restenosis in 3 out of 32 interventions representing
9.4%. 2 restenoses developed in the distal main branch and 1 in the side branch.
All 3 patients had received DCB treatment for LM/LAD/LCX bifurcations and
suffered from most severe coronary artery disease, but had been non eligible for
bypass surgery for various reasons.
Conclusions: DCB only intervention without additional stenting seems to be a
save therapy for de novo bifurcation lesions and even LM bifurcations respond
favorably.
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Background: Percutaneous intervention (PCI) for unprotected left main lesions
(ULM) is escalating with the improvement in device technology. However,
heavily calciﬁcated lesions remain one of the main limitations for PCI, which were
associated with in-stent restenosis and stent thrombosis. However, there is a little
data regarding PCI for severe calciﬁed ULM lesion using rotational atherectomy
(ROTA). This study aims to evaluate safety and feasibility of PCI using ROTA for
ULM.
Methods: Between January 2005 and November 2011, consecutive 63 patients treated
with DES implantation using ROTA were included in this study. Study end points are
procedural success, cardiac death, target lesion revascularization (TLR) and TLR for
main branch (TLR-MB) including within LM toward LAD at 1-year.
Results: Age was 71.38.8 years old, male gender is 42 (66.7%), diabetes mellitus is
8 (12.7%), and hemodialysis (HD) is 13 (20.6%). Mean EuroScore was 5.60 and
SYNTAX score was 35.5%. There is no peri-procedural death and perforation, while
peri-procedural MI occurred in 6 (9.5%). At 1-year, cardiac-death occurred in
5 (7.9%) patients and TLR occurred in 16 (25.4%). Notably, TLR-MB occurred in 9
(14.3%) and was more frequently observed in HD patients as compared to non
hemodialysis (non HD) patients (38.5% vs. 4.0%, p¼0.001). IVUS ﬁnding demon-
strated the majority of patients achieved optimal stent expansion with MSA above
8.2cm2 at LM and above 6.3 cm2at proximal LAD. However, TLR-MB was neces-
sary in 5 (7.9%) patients on HD despite optimal stent expansion.acts/POSTER/Bifurcation and Left Main Interventions B127
